Literature DB >> 19008404

Substitution of the myristoylation signal of human immunodeficiency virus type 1 Pr55Gag with the phospholipase C-delta1 pleckstrin homology domain results in infectious pseudovirion production.

Emiko Urano1,2, Toru Aoki2, Yuko Futahashi2, Tsutomu Murakami2, Yuko Morikawa1, Naoki Yamamoto2, Jun Komano2.   

Abstract

The matrix domain (MA) of human immunodeficiency virus type 1 Pr55Gag is covalently modified with a myristoyl group that mediates efficient viral production. However, the role of myristoylation, particularly in the viral entry process, remains uninvestigated. This study replaced the myristoylation signal of MA with a well-studied phosphatidylinositol 4,5-biphosphate-binding plasma membrane (PM) targeting motif, the phospholipase C-delta1 pleckstrin homology (PH) domain. PH-Gag-Pol PM targeting and viral production efficiencies were improved compared with Gag-Pol, consistent with the estimated increases in Gag-PM affinity. Both virions were recovered in similar sucrose density-gradient fractions and had similar mature virion morphologies. Importantly, PH-Gag-Pol and Gag-Pol pseudovirions had almost identical infectivity, suggesting a dispensable role for myristoylation in the virus life cycle. PH-Gag-Pol might be useful in separating the myristoylation-dependent processes from the myristoylation-independent processes. This the first report demonstrating infectious pseudovirion production without myristoylated Pr55Gag.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19008404      PMCID: PMC2885030          DOI: 10.1099/vir.0.2008/004820-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


The N-terminal region [p17MA, matrix (MA) domain] of human immunodeficiency virus type 1 (HIV-1) Pr55Gag (Gag), a structural protein with multiple roles in the virus life cycle (Swanstrom & Wills, 1997), is covalently modified with a myristyol group that aids in plasma membrane (PM) targeting. Removal of this region leads to inefficient Gag targeting to the PM, resulting in dramatically reduced virus production (Bryant & Ratner, 1990; Göttlinger ; Pal ; Zhou ). Although viral particles can be produced by substituting MA with heterologous PM-targeting motifs, such substitution mutants show markedly reduced infectivity (Jouvenet ; Scholz ), probably due to an active role of MA in viral entry (Kiernan ; Wang ). However, direct experimental evidence of a viral entry-specific role for MA myristoylation is lacking. Such specific roles of Gag myristoylation can only be determined by separating the myristoylation-dependent PM-targeting function from other MA-associated functions. We constructed a mutant gag expression plasmid where the myristoylated region of Gag was replaced with the N-terminal pleckstrin homology (PH) domain of phospholipase C-δ1 (PLCδ1), a well-studied cellular PM-targeting motif that functions similarly to the myristoyl moiety. PLCδ1 is a member of a family of inositol phospholipid-specific PLC isozymes involved in transducer-mediated intracellular responses (Berridge, 1993). The ∼120 aa PH domain can bind to phosphatidylinositol 4,5-biphosphate [PI(4,5)P(2)] and localize to the PM with high affinity and specificity (Ferguson ; Fiorentini ; Harlan , 1995; Rhee, 2001; Yagisawa ), and green fluorescent protein-bound PLCδ1 PH domains have been used to visualize the PM in living cells (Stauffer ; Tall ). We used a codon-optimized HIV-1 gag–pol expression vector (pgag–pol) for genetic modification of gag, as pgag–pol increases Gag expression and facilitates protein analyses (Wagner ). The substituted mutant retained an intact MA, with the exception of two N-terminal amino acid mutations (ATG→CTG and GGC→GCG), resulting in an MG→LA mutation to knock out the myristoylation signal of Gag and prevent internal translational initiation (Fig. 1a). The PLCδ1 PH domain residues 1–175 (Stauffer ) were linked to the LA–Gag N terminus by the amino acids PRAEFT, creating a PH–gag–pol expression vector (pPH-gag-pol, Fig. 1a). A control PH domain mutant (PH4A) had mutations at aa 54–57 (ESRK→AAAA; Fig. 1a); these residues are responsible for the PH domain–PI(4,5)P(2) interaction (Ferguson ). PH–Gag, PH4A–Gag and their cleaved products were detected in transfected 293T cell lysates with mouse monoclonal antibodies specific for the p24CA (capsid) domain (anti-p24CA; NIH AIDS Research and Reference Reagent Program) and MA domain (anti-p17MA; Advanced Biotechnologies) (Fig. 1b). PH–Gag cleavage was more efficient than that of Gag, suggesting efficient PM targeting of PH–Gag (Fig. 1b). The Gag protein levels in the pPH4A-gag-pol-transfected cell lysate were higher than those in pgag-pol- and pPH-gag-pol-transfected cell lysates when adjusted for the amount of protein loaded, indicating the low virus-like particle (VLP) production efficiency by PH4A–Gag (Fig. 1b).
Fig. 1.

Viral production by the gag–pol expression vectors. (a) The genetic structure of the pgag-pol, pPH-gag-pol and pPH4A-gag-pol expression vectors, and the amino acid sequence of the PH–Gag junction are shown. The N-terminal PH domain of PLCδ1 (aa 1–175) was fused to LA–Gag, linked by a 5 aa spacer (shown in grey). The MG→LA mutation to knock out the myristoylation signal of Gag (myr signal k.o.) is underlined. Four alanine mutations were introduced to replace the ESRK sequence (dotted line) to create the PH4A mutant. (b) Protein expression from pgag-pol (WT), pPH-gag-pol (PH) and pPH4A-gag-pol (PH4A) in transfected 293T cell lysates and Gag cleavage in the virions were examined by Western blot analysis using anti-p24CA or anti-p17MA antibodies. Note that the anti-p17MA antibody recognizes the cleaved p17MA protein only. The band denoted as PH–MA–CA in the virion detected by the anti-p24CA antibody (lower left panel) possibly overlaps with a faint Gag signal derived from PH–Gag and PH4A–Gag from which the PH and PH4A domains have been cleaved. (c) Immunofluorescence assay showing the distribution of Gag, PH–Gag and PH4A–Gag in 293T cells transfected with the respective expression plasmid. Red and blue represent p24CA and the Hoechst 33258-stained nucleus, respectively. Bars, 10 μm.

The intracellular distribution of Gag, PH–Gag and PH4A–Gag was analysed by immunofluorescence microscopy of transfected 293T cells (Fig. 1c). Transfected cells were grown for 24 h, fixed (4 % formaldehyde), permeabilized (0.1 % Triton X-100 for 5–30 min) and incubated with mouse anti-p24CA and goat anti-mouse antibodies (GE Healthcare Bio-Sciences) conjugated to streptavidin–Alexa Fluor 555 (Invitrogen). Cells were stained with Hoechst 33258, mounted and analysed using confocal microscopy as described previously (Futahashi ). Gag was found to be distributed throughout the cytoplasm and at the cell periphery. In contrast, PH–Gag signals were mostly detected at the cell periphery and PH4A–Gag was distributed homogeneously in the cytoplasm. These data clearly showed that PH–Gag targeted the PM more efficiently than Gag, consistent with the Western blot analysis (Fig. 1b). These results also suggested that the efficient PM targeting of PH–Gag depends on the ability of the PH domain to bind PI(4,5)P(2). Similar observations were made in NP2 and COS7 cells. VLP production was also examined. Tissue culture supernatants of pgag-pol-, pPH-gag-pol- or pPH4A-gag-pol-transfected 293T cells were passed through nitrocellulose filters (0.45 μm) and the virions were collected by centrifugation (541 000  for 1 h). Viral antigens, except for PH4A, were detected with anti-p24CA and anti-p17MA antibodies (Fig. 1b). Gag and PH–Gag were further processed by the viral proteases in the virions compared with the cell lysates, as indicated by the increased signals for CA and MA relative to Gag. Interestingly, approximately one-fifth of the PH–Gag in the virion was cleaved close to the PH–MA junction. Presumably, the amino acid sequence at the C end of the PH domain ELQN/FLKE (aa 164–171, where the protease cleaves at the N–F junction) served as a viral protease recognition site as it matched the substrate consensus sequence and resembled the NC–p1 junction, RQAN/FLGK (de Oliveira ; Swanstrom & Wills, 1997). Alternatively, the N terminus of LA–Gag (EFTL/AADS) might be targeted by the viral protease. Thus, the MA released from PH–MA, designated MA*, possibly has 10 aa attached to its N terminus. The VLP production efficiency was quantified as the concentration of CA in transfected 293T cell culture supernatants relative to that in cell lysates using a p24 ELISA (Zeptometrics). When the CA concentrations of the virion fractions were normalized to those of the cell lysates, the pPH-gag-pol viral production efficiency was 3.2-fold higher than that of pgag-pol (3.2±2.0-fold, n=14, P<0.001 by Wilcoxon's matched pairs rank test; representative experiments are shown in Table 1). In contrast, pPH4A-gag-pol produced viral particles less efficiently than pgag-pol (0.09±0.07-fold, n=6, P<0.05 by Wilcoxon's matched pairs rank test; representative experiments are shown in Table 1). These data were consistent with the Western blot analysis (Fig. 1b).
Table 1.

Efficiency of virus production from 293T cells transfected with pgag-pol, pPH-gag-pol or pPH4A-gag-pol expression vector

ExperimentPlasmidp24CA (ng per well)*Virus production efficiency (B/A)Fold increase relative to pgag-pol
Cell lysate (A)Culture supernatant (B)
1pgag-pol4 0434 8691.204
pPH-gag-pol1 9898 3634.2063.49
pPH4A-gag-pol3 1751030.0330.03
2pgag-pol3 5213 8871.104
pPH-gag-pol2 6387 6882.9142.64
pPH4A-gag-pol5 9131 1250.1900.17
3pgag-pol3 3594 1601.239
pPH-gag-pol1 4545 1723.5582.87
pPH4A-gag-pol4 226750.0180.01
4pgag-pol9 6668 9960.931
pPH-gag-pol4 69918 2733.8894.18
pPH4A-gag-pol5 5275340.0970.10

*Cells grown in six-well plates were transfected using Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen).

To characterize the physical properties of PH–Gag–Pol VLPs, we measured the specific density of virions and examined the virion morphology. Firstly, the VLPs were subjected to 20–70 % (w/w) equilibrium sucrose gradient centrifugation (120 000  for 16 h) and fractions were recovered from the bottom to the top. The peak fraction containing the viral CA antigen was determined by p24 ELISA. Gag–Pol and PH–Gag–Pol VLPs were detected in fractions with densities of 1.15±0.01 (n=5) and 1.16±0.01 (n=4) g ml−1, respectively (not statistically significant; representative experiments are shown in Fig. 2a). Secondly, ultrathin sections of fixed 293T cells (2 % glutaraldehyde, 2 % osmium tetroxide) transfected with pgag-pol or pPH-gag-pol were imaged by transmission electron microscopy (JEM1200EX at 80 kV or JEM2000EX at 100 kV; JEOL). The PH–Gag–Pol and Gag–Pol VLP diameters were almost identical (Fig. 2b). Virion budding structures showed that the electron-dense layer, which represented multimerized Gag, of the PH–Gag–Pol VLP was slightly separated from the viral envelope compared with that of the Gag–Pol VLP (Fig. 2b). This indicated that the PH domain was positioned between the viral envelope and the electron-dense layer. In contrast, the morphologies of the mature PH–Gag–Pol and Gag–Pol virions were similar, suggesting that myristoylation is dispensable for mature virion morphology and that the PH–Gag–Pol virion may be infectious.
Fig. 2.

Physical and biological properties of PH–Gag–Pol VLPs. (a) The virions produced by the pgag-pol (WT) and pPH-gag-pol (PH) expression vectors were analysed by equilibrium sucrose density-gradient centrifugation. The virion-containing fraction was determined by an ELISA detecting p24CA. Representative data from four to five independent experiments are shown. In this experiment, WT (filled circles) and PH (open circles) VLPs migrated in the 1.152 or 1.162 g ml−1 density fractions, respectively. (b) Transmission electron microscopy images of 293T cells transfected with pgag-pol (WT) or pPH-gag-pol (PH). Representative images are shown. (c) Incorporation of HIV-1 Env (upper panel) and VSV-G (lower panel) into Gag–Pol (WT) and PH–Gag–Pol (PH) virions. The virion fractions were subjected to Western blot analysis detecting gp120, VSV-G and p24CA. (d) The early phase of the HIV-1 life cycle is supported by PH–Gag–Pol. 293T cells were exposed to virus-containing culture supernatants with similar CA concentrations (270 and 220 ng ml−1 for Gag–Pol and PH–Gag–Pol, respectively), and luciferase activities were measured at 2–3 days post-infection as relative light units (RLU). The luciferase activities of PH–Gag–Pol (PH) and Gag–Pol (WT) virus-infected cells were almost identical (left graph). The luciferase transduction by WT (bars 1 and 2) and PH (bars 3 and 4) pseudovirions was performed in the presence of nevirapine (NVP, bars 1 and 3) or TAK-779 (bars 2 and 4). The luciferase signals decreased in the presence of NVP for both WT (bar 1) and PH (bar 3) but not in the presence of TAK-779 for both WT (bar 2) and PH (bar 4), respectively. Representative data from several independent experiments are shown. Asterisks indicate statistical significance (P<0.01, n=3, Student's t-test).

We examined HIV-1 Env incorporation into the PH–Gag–Pol virion. To do this, we used codon-optimized gp160 (p96ZM651gp160-opt; NIH AIDS Research and Reference Reagent Program). The PH–Gag–Pol virion incorporated HIV-1 Env less efficiently than the Gag–Pol virion as demonstrated by Western blot analysis detecting CA and gp120 (anti-gp120 antibodies from Santa Cruz Biotechnology; Fig. 2c). This was presumably because PH interfered with the MA–Env interaction. Alternatively, PH may actively incorporate cellular proteins that block efficient Env incorporation into virions. We were unable to evaluate the entry efficacy of PH–Gag–Pol virions pseudotyped by HIV-1 Env because of the limit of detection. PH–Gag–Pol virion infectivity was re-examined by virions pseudotyped with vesicular stomatitis virus G glycoprotein (VSV-G). The incorporation efficiencies of VSV-G into Gag–Pol and PH–Gag–Pol virions were similar (anti-VSV-G antibody from Sigma; Fig. 2c). The lentiviral vector system was used to test this, as HIV-1 provirus gene modifications often fail to produce infectious virions, probably due to viral gene dysregulation. 293T cells were transfected with expression plasmids for Gag–Pol, VSV-G (Komano ), Rev and Vpu (a generous gift from Dr H. Göttlinger, University of Massachusetts Medical School, MA, USA), and with a packaging vector encoding a luciferase expression cassette. The HIV-1-based vector expressing firefly luciferase upon infection was recovered 2 days post-transfection. 293T cells were exposed to virus-containing culture supernatants with similar CA concentrations, and luciferase activities were measured at 2–3 days post-infection. When viral preparations with similar p24 concentrations were used, the luciferase activities of PH–Gag–Pol and Gag–Pol virus-infected cells were almost identical to each other (Fig. 2d, left graph). Luciferase expression was blocked by the non-nucleoside reverse transcriptase inhibitor nevirapine (NVP; Boehringer Ingelheim) but not by the CCR5 inhibitor (TAK-779; NIH AIDS Research and Reference Reagent Program), suggesting that gene transduction was mediated by viral infection (Fig. 2d, right panel). Similar results were obtained in several independent experiments. Thus, the PLCδ1 PH domain can functionally replace the HIV-1 Gag myristoylation signal to support both viral production and entry processes, and this myristoylation is dispensable for MA function in the early phase of the virus life cycle. This is the first report describing an infectious pseudovirion without myristoylated Gag. Given that PH–Gag can enhance virus production, HIV-1 with PH–Gag might have been expected to be selected in nature. This is not the case, presumably because the addition of PH to the HIV-1 genome would increase its genome size close to the upper limit that can be incorporated into the retroviral particle, leading to a decrease in genome uptake efficiency, which is clearly a growth disadvantage, despite the enhanced virus production with PH-Gag. More importantly, PH–Gag is unable to incorporate HIV-1 Env efficiently enough to support the production of fully infectious virions. Our data point to the selective advantage of myristoylated Gag in viral evolution. The myristoylation-dependent Gag–PM association [maximal dissociation constant (Kd) of ∼0.5–1.0×10−5 M] is presumably important for Gag multimerization at the PM (Provitera ). After the first contact of Gag with the PM, the membrane binding of Gag is assumed to be stabilized by the GagPI(4,5)P(2) interaction (Ono ; Saad ). The multimerization of Gag appears to induce a conformational change in MA to expose myristoyl groups to enhance the PM targeting of Gag. The higher-order Gag multimerization is probably facilitated by the increased local concentrations of Gag at the PM. Although Gag and PH–Gag are similar to the extent that PI(4,5)P(2) is involved in their PM association, Gag binds to one of the acyl chains of PI(4,5)P(2), as modelled previously (Saad ), whilst the PH domain binds the phosphorylated inositol group (Lemmon ). The Kd of binding between the PLCδ1 PH domain and PI(4,5)P(2) (∼1–2×10−6 M; Lemmon ) suggests that the primary force driving PH–Gag to the PM is at least 2.5-fold stronger than that of myristoylation-mediated PM targeting of Gag. This might be one reason why PH–Gag–Pol was 3.2-fold more efficient at virion production than Gag–Pol. Our data suggest that the myristoyl group-dependent Gag–PM affinity is not a prerequisite for efficient Gag assembly at the PM or for viral production. The MA has multiple functions throughout the virus life cycle (reviewed by Bukrinskaya, 2007; Fiorentini ; Hearps & Jans, 2007; Klein ). In the PH–Gag–Pol virion, approximately one-fifth of the PH–MA was unanchored from the PM as MA* (Fig. 1b), which might accompany the pre-integration complex to support nuclear targeting. Using PH–Gag–Pol might enable separation of myristoylation-dependent and -independent MA functions, particularly during the entry phase. PH–Gag–Pol might also be useful for producing high-titre lentiviral vectors or for studying Gag trafficking in cells that poorly support PM targeting of myristoylated Gag, such as rodent cells. Furthermore, functional assays comparing the virus production of Gag–Pol and PH–Gag–Pol might enable the identification of chemical inhibitors or cellular factors specifically targeting myristoylated Gag.
  29 in total

Review 1.  HIV-1 matrix protein: a mysterious regulator of the viral life cycle.

Authors:  Alissa Bukrinskaya
Journal:  Virus Res       Date:  2007-01-08       Impact factor: 3.303

2.  Separate elements are required for ligand-dependent and -independent internalization of metastatic potentiator CXCR4.

Authors:  Yuko Futahashi; Jun Komano; Emiko Urano; Toru Aoki; Makiko Hamatake; Kosuke Miyauchi; Takeshi Yoshida; Yoshio Koyanagi; Zene Matsuda; Naoki Yamamoto
Journal:  Cancer Sci       Date:  2007-03       Impact factor: 6.716

3.  Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle.

Authors:  R E Kiernan; A Ono; G Englund; E O Freed
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.

Authors:  H G Göttlinger; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

5.  Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.

Authors:  M Bryant; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

6.  Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate.

Authors:  J E Harlan; P J Hajduk; H S Yoon; S W Fesik
Journal:  Nature       Date:  1994-09-08       Impact factor: 49.962

Review 7.  Functions of the HIV-1 matrix protein p17.

Authors:  Simona Fiorentini; Elena Marini; Sonia Caracciolo; Arnaldo Caruso
Journal:  New Microbiol       Date:  2006-01       Impact factor: 2.479

8.  Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly.

Authors:  Jamil S Saad; Jaime Miller; Janet Tai; Andrew Kim; Ruba H Ghanam; Michael F Summers
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-13       Impact factor: 11.205

9.  Inhibiting the Arp2/3 complex limits infection of both intracellular mature vaccinia virus and primate lentiviruses.

Authors:  Jun Komano; Kosuke Miyauchi; Zene Matsuda; Naoki Yamamoto
Journal:  Mol Biol Cell       Date:  2004-09-22       Impact factor: 4.138

Review 10.  Regulating the functions of the HIV-1 matrix protein.

Authors:  Anna C Hearps; David A Jans
Journal:  AIDS Res Hum Retroviruses       Date:  2007-03       Impact factor: 2.205

View more
  10 in total

1.  Effect of multimerization on membrane association of Rous sarcoma virus and HIV-1 matrix domain proteins.

Authors:  Robert A Dick; Elena Kamynina; Volker M Vogt
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

2.  Gag induces the coalescence of clustered lipid rafts and tetraspanin-enriched microdomains at HIV-1 assembly sites on the plasma membrane.

Authors:  Ian B Hogue; Jonathan R Grover; Ferri Soheilian; Kunio Nagashima; Akira Ono
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

3.  Lentivirus pre-packed with Cas9 protein for safer gene editing.

Authors:  J G Choi; Y Dang; S Abraham; H Ma; J Zhang; H Guo; Y Cai; J G Mikkelsen; H Wu; P Shankar; N Manjunath
Journal:  Gene Ther       Date:  2016-04-07       Impact factor: 5.250

4.  Novel postentry inhibitor of human immunodeficiency virus type 1 replication screened by yeast membrane-associated two-hybrid system.

Authors:  Emiko Urano; Noriko Kuramochi; Reiko Ichikawa; Somay Yamagata Murayama; Kosuke Miyauchi; Hiroshi Tomoda; Yutaka Takebe; Milan Nermut; Jun Komano; Yuko Morikawa
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

5.  Virus-Like Particles Derived from HIV-1 for Delivery of Nuclear Proteins: Improvement of Production and Activity by Protein Engineering.

Authors:  Marc-André Robert; Viktoria Lytvyn; Francis Deforet; Rénald Gilbert; Bruno Gaillet
Journal:  Mol Biotechnol       Date:  2017-01       Impact factor: 2.695

6.  The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.

Authors:  Tsutomu Murakami; Sei Kumakura; Toru Yamazaki; Reiko Tanaka; Makiko Hamatake; Kazu Okuma; Wei Huang; Jonathan Toma; Jun Komano; Mikiro Yanaka; Yuetsu Tanaka; Naoki Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

7.  Trimer Enhancement Mutation Effects on HIV-1 Matrix Protein Binding Activities.

Authors:  Ayna Alfadhli; Andrew Mack; Christopher Ritchie; Isabel Cylinder; Logan Harper; Philip R Tedbury; Eric O Freed; Eric Barklis
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

8.  Therapeutic potential of HIV protease-activable CASP3.

Authors:  Kosuke Miyauchi; Emiko Urano; Mari Takizawa; Reiko Ichikawa; Jun Komano
Journal:  Sci Rep       Date:  2012-04-11       Impact factor: 4.379

9.  The phosphorylation of HIV-1 Gag by atypical protein kinase C facilitates viral infectivity by promoting Vpr incorporation into virions.

Authors:  Ayumi Kudoh; Shoukichi Takahama; Tatsuya Sawasaki; Hirotaka Ode; Masaru Yokoyama; Akiko Okayama; Akiyo Ishikawa; Kei Miyakawa; Satoko Matsunaga; Hirokazu Kimura; Wataru Sugiura; Hironori Sato; Hisashi Hirano; Shigeo Ohno; Naoki Yamamoto; Akihide Ryo
Journal:  Retrovirology       Date:  2014-01-22       Impact factor: 4.602

10.  Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases.

Authors:  Yujia Cai; Rasmus O Bak; Jacob Giehm Mikkelsen
Journal:  Elife       Date:  2014-04-24       Impact factor: 8.140

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.